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ciation for Thoracic Surgery(
doi:10.1016/j.jtcvs.2006.11.019bjective: To determine, through meta-analysis, whether off-pump coronary artery
ypass, including minimally invasive off-pump coronary artery bypass, improves
hort-term and midterm outcomes compared with percutaneous coronary interven-
ion for single- or double-vessel coronary artery disease.
ethods: The primary outcome was need for coronary reintervention at 1 to 5 years.
econdary outcomes included all major clinical morbidities and resource utilization.
comprehensive search was undertaken to identify all randomized trials of
ff-pump coronary artery bypass versus percutaneous coronary intervention.
EDLINE, Cochrane Library, EMBASE, and abstract databases were searched up
o May 2006. All randomized trials comparing off-pump coronary artery bypass
sternotomy or minimally invasive) versus percutaneous coronary intervention and
eporting at least one predefined outcome were included. Odds ratios (OR, 95%
onfidence intervals [CI]) and weighted mean differences (WMD, 95% CI) were
nalyzed.
esults: Six trials involving 989 patients were included. Compared with percuta-
eous coronary intervention, off-pump coronary artery bypass decreased angina
ecurrence (OR 0.54, 95% CI 0.34–0.87) and need for reintervention at 1 to 5 years
OR 0.24, 95% CI 0.15–0.40). Major adverse coronary events were significantly
educed (OR 0.44, 95% CI 0.30–0.63) and event-free survival was significantly
ncreased at 1 to 5 years (OR 2.32, 95% CI 1.62–3.32) for off-pump coronary artery
ypass versus percutaneous coronary intervention. Coronary stenosis at 6 months
as reduced with off-pump coronary artery bypass compared with percutaneous
oronary intervention (OR 0.31, 95% CI 0.18–0.55). Hospital stay was significantly
ncreased with off-pump coronary artery bypass versus percutaneous coronary
ntervention (WMD 4.03, 95% CI 2.37–5.70). Quality of life favored off-pump
oronary artery bypass in some domains but was reported in few studies. Death,
yocardial infarction, and stroke did not significantly differ.
onclusions: In single- or double-vessel disease, off-pump coronary artery
ypass improved short-term and midterm clinical outcomes compared with
ercutaneous coronary intervention but was associated with an increased length
f hospital stay.
lthough it has been demonstrated that conventional coronary artery bypass
surgery (CCAB) may prolong life and reduce symptoms, these benefits are
tempered by risks including mortality (2%–5%), stroke (2%), transfusions30%–90%), atrial fibrillation (30%), and neurocognitive dysfunction (50% 75%).1-4
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CDonsequently, there has been an upsurge of interest in safer
lternatives to CCAB, including percutaneous coronary inter-
ention with stenting (PCI) and off-pump beating heart bypass
urgery (OPCAB), with avoidance of cardiopulmonary by-
ass.5,6 Several randomized trials have compared PCI with
CAB and demonstrated increased rates of angina or need for
eintervention in the PCI cohort,1,7-11 whereas overall costs
ere reduced in the short term.9 Outcomes with PCI were
enerally worse in patients with diabetes and in those with
ultivessel disease.12,13 PCI is most commonly performed in
imited target vessels; thus it may not be appropriate to com-
are its outcomes with multivessel CCAB.14
Comparisons of OPCAB and CCAB surgery have demon-
trated improvement in short-term outcomes favoring OPCAB
or atrial fibrillation, blood transfusion, and length of hospital
tay in patients unselected for risk (ie, in mixed-risk patient
opulations).15 There is further evidence indicating OPCAB
mproves mortality, morbidity, and resource utilization when
ompared with CCAB in high-risk patients.16 However, pa-
ients undergoing OPCAB had slightly fewer anastomoses,
uggesting some limitations for multiple target revasculariza-
ions using OPCAB surgical technique.15 Therefore, compar-
ng PCI with OPCAB would seem the more relevant compar-
son in patients with one- or two-vessel coronary artery
isease.
We sought to determine, through systematic review with
eta-analysis of all relevant randomized trials, whether
PCAB reduces mortality, morbidity, or resource utiliza-
ion when compared with PCI.
aterials and Methods
earching for Trials
his meta-analysis was performed in accordance with QUOROM*
ecommendations and according to a protocol that pre-specified
Abbreviations and Acronyms
CABG  coronary artery bypass grafting
CCAB  conventional coronary artery bypass
CROQ  Coronary Revascularization and Outcome
Questionnaire
EQ-5D  EuroQOL
LOS  length of stay
MACE major adverse coronary events
MIDCABminimally invasive off-pump coronary
artery bypass
OPCAB  off-pump coronary artery bypass
OR  odds ratio
PCI  percutaneous coronary intervention
SAQ  Seattle Angina Questionnaire
SF-36  short-form health survey
WMD  weighted mean differencesQUOROM  Quality of Reporting of Meta-analyses,
E
f
24 The Journal of Thoracic and Cardiovascular Surgery ● Marcutcomes, search strategies, inclusion criteria, and statistical anal-
ses.17 A search was undertaken in accordance with Cochrane
ollaboration recommendations to identify all published or unpub-
ished randomized trials of OPCAB versus CCAB or PCI, in any
anguage. MEDLINE, Cochrane CENTRAL, EMBASE, Current
ontents, DARE, NEED, and INAHTA† databases were searched
rom the date of their inception to May 2006. Search terms
ncluded variants of off-pump, minimally invasive, beating heart,
nd coronary artery bypass. Tangential electronic exploration of
elated articles and hand searches of bibliographies, scientific
eeting abstracts, and related journals were also performed.
nclusion Criteria
tudies were included if they met each of the following: (1) adult
atients with single- or multiple-vessel coronary artery disease
uitable for revascularization with either OPCAB or PCI; (2)
andomized allocation to OPCAB on the beating heart (via thora-
otomy or minimally invasive technique) versus PCI (with or
ithout stenting); and (3) reporting at least one pertinent clinical or
conomic outcome. Blinded and unblinded studies were included,
n any language. Hybrid (ie, OPCAB plus PCI) and robotically
ssisted surgery studies were excluded.
ata Extraction
wo authors independently identified trials for inclusion and ex-
racted information on demographics, interventions, and outcomes.
uthors of included trials were contacted when necessary to clar-
fy data and to identify multiple publications. Two reviewers
ndependently assigned each trial a Jadad quality score18 that
valuates randomization, blinding, and completeness of follow-up
maximum score, 5). Disagreements were resolved by consensus.
nd Points
he primary outcome was defined as the need for reintervention
or ischemia. Secondary outcomes included postoperative inci-
ence of major adverse coronary events (MACE), all-cause mor-
ality, stroke, acute myocardial infarction, atrial fibrillation, renal
ailure, need for inotropes, need for intra-aortic balloon pump,
ediastinitis or wound infection, respiratory infections, angina
ecurrence, restenosis, need for transfusions, re-exploration for
leeding, neurocognitive dysfunction, intensive care unit (ICU)
ength of stay (LOS), hospital LOS, hospital costs, and quality of
ife (QOL). The original study authors’ definition of MACE was
sed and usually included the composite of death, acute myocar-
ial infarction, and need for reintervention, and sometimes in-
luded stroke. Reintervention for ischemia was defined as require-
ent for either PCI or CABG occurring anytime throughout the
rial. Stenosis and atrial fibrillation were defined according to study
uthors’ definitions. Acute myocardial infarction was defined per
tudy authors’ definitions of new-onset infarction using electrocar-
iographic or enzymatic criteria. Mediastinitis and wound infec-
ion were defined as deep or superficial wound infections of the
hest or catheter-related infections; they excluded leg wound in-
ections. Respiratory infection was defined according to authors’
efinitions, whether or not confirmed by chest x-ray film. Need for
DARE  Database of Abstracts of Reviews of Effects; NEED  NHS
conomic Evaluation Database; INAHTA International Network of Agencies
or Health Technology Assessment.
h 2007
ab
s
o
d
i
o
c
t
h
h
S
O
e
w
a
a
w
d
v
p
o
W
a
l
t
t
h
V
s
D
I
i
b
A
C
n
e
s
w
v
s
e
i
s
t
v
w
r
R
A
p
a
2
v
h
p
u
w
w
l
a
d
i
i
n
m
F
R
i
Bainbridge et al Surgery for Acquired Cardiovascular Disease
A
CDtransfusion was defined as the number of patients requiring red
lood cell transfusion. Renal failure was defined as a new rise in
erum creatinine of more than 50%, decline in creatinine clearance
f more than 50%, or requirement of dialysis. Since no standard
efinition exists for neurocognitive dysfunction, we planned to
nclude only studies reporting neurocognitive dysfunction dichot-
mously, and when tests in accordance with the statement of
onsensus were used.19 Duration of ventilation was measured from
he end of surgery to the time of tracheal extubation. ICU LOS and
ospital LOS were measured from the end of surgery until ICU or
ospital discharge, respectively.
tatistical Analysis
utcomes were analyzed as dichotomous variables, with the
xception of duration of ventilation, LOS, costs, and QOL,
hich were analyzed as continuous variables when the mean
nd standard deviation were reported. For dichotomous vari-
bles, odds ratios and 95% confidence intervals (OR, 95% CI)
ere calculated. For continuous variables, the weighted mean
ifference (WMD, 95% CI) was calculated for duration of
entilation and LOS. Standardized mean differences were
lanned to be calculated for costs and QOL; however, these
utcomes were insufficiently reported for combined analyses.
hen significant differences were found for proportions, the
bsolute risk reduction and number needed to treat were calcu-
ated.20 Heterogeneity was explored using I2 . The I2 indicates
he proportion of variability between trials that cannot be at-
ributable to chance alone; it provides an improved measure of
etereogeneity between trials that is not limited by power.21,22
alues of I2 higher than 50% were considered to indicate
ignificant heterogeneity between trials.
For each outcome, the Mantel–Haenszel (fixed effect) or
erSimonian and Laird (random effects) model was used when
2 suggested lack (50%) or presence (50%) of heterogene-
ty, respectively. Pooled effect estimates and heterogeneity
etween studies were analyzed by use of Comprehensive Meta-
nalysis (Englewood, NJ, 2002) and RevMan (v4.2, Cochrane
ollaboration, 2003). Other than for the Q-test, statistical sig-
ificance was defined as P  .05 or a confidence interval that
xcluded the possibility of no effect. All tests of statistical
ignificance were 2-sided. Whenever possible, data analysis
as by intention-to-treat.
Subgroup analysis was planned for single- versus multiple-
essel disease and for drug-eluting stents versus bare metal
tents. Sensitivity analysis was planned to explore the potential
ffect of trial quality, publication status, and patients excluded
n non–intention-to-treat trials using a worst-case scenario as-
umption. Publication bias was explored through visual inspec-
ion of funnel plots in which the inverse of the estimated
ariance of the natural logarithm of the adjusted relative risk
as plotted against the natural logarithm of the adjusted relative
isk for each outcome.23
esults
total of 11 papers reporting on 6 trials involving 989
atients provided data for this meta-analysis (Figure 1
nd Table 1).24-34 The median Jadad score was 3 (range t
The Journal of Thoracic–3).18 Significant heterogeneity was found for reinter-
ention at 6 months, angina recurrence at 6 months, and
ospital LOS. Funnel plots showed no clear evidence of
ublication bias for any end point, although they were
nderpowered to do so. Patient demographics at baseline
ere similar (Table 2).
Although 5 of 6 trials comparing PCI versus OPCAB
ere exclusively of left anterior descending stenting versus
eft internal thoracic arterytoleft anterior descending
nastomosis, one trial included patients with multivessel
isease.33 The mean number of stents implanted per patient
n this latter trial was 1.44.33 The majority of stents were
mplanted for stenosis in the left anterior descending coro-
ary artery. Five trials used MIDCAB technique in the
ajority of patients in the surgical arm.24,25,27,30,34 In one
Potentially relevant RCTs
identified and screened
for retrieval (n  567)
RCTs excluded (n  553)
• non-random design, n  538
• combined procedure, n  2
• robotic procedure, n  3
• no off-pump group, n  9
• no PCI group, n  1
RCTs retrieved for more
detailed evaluation
(n  14)
RCTs excluded (n  4)
• non-random design, n  3
• no PCI, n  1
Potentially appropriate
RCTs to be included in
the meta-analysis
(n  11)
RCTs excludedˆ from the meta-
analysis, with reasons
• Duplicate data, n  5
RCTs with usable
information included in
meta-analysis (n  6)
ˆWhen duplicate studies provided new data beyond that available in the
index publication, the additional data was included and attributed to the
index trial. For this reason, multiple citations appear in Table 1 when one
trial is reported across more than one paper.
igure 1. Identification of eligible trials: QUOROM flow chart.
CTs, Randomized clinical trials; PCI, percutaneous coronary
ntervention.rial, surgical access to the heart was achieved via median
and Cardiovascular Surgery ● Volume 133, Number 3 625
sl
o
s
c
s
e
p
l
o
a
w
a
O
c
t
p
t
C
i
(
T
A
C
D
D
E
R
H
S
A
C
L
a
T
A
F
D
H
S
H
C
M
p
Surgery for Acquired Cardiovascular Disease Bainbridge et al
6
A
CDternotomy in 67%, left anterior thoracotomy in 30%, and
eft posterolateral, xiphoid laparotomy, or partial sternot-
my in the remainder.33 While one trial allowed either
tenting or angioplasty,24 all patients except 6 in the PCI
ohort received a stent. Five trials employed bare metal
ABLE 1. Characteristics of included trials
uthor N
Jadad
score Vessels
isowski25,26
(02)
100 2,0,1 1 Isolated A-, B-ty
LAD
iegeler27,28
(02)
220 2,0,1 1 Isolated proxima
EF  35%
renth29–32
(02)
102 2,0,1 1 Isolated LAD ste
CCS class 2 o
CABG
efting33 (03)
(OctoStent)
280 2,0,1 1 Included single-
disease, stab
(Braunwald c
main stem ste
emergency re
MI, previous
revasculariza
eeves24 (04)
(AMIST)
100 2,0,1 1 Included isolate
 50%, elect
emergency (r
LVEF  30%,
revasculariza
LAD.
ong34 (05) 189 1,0,1 1 Included isolate
(70% of the
proximal LAD
coronary reva
occlusion of L
ummary,
OPCAB vs
PCI (6
studies)
989 Median: 3 1 Mainly isolated
MI, Acute myocardial infarction; AMIST, Angioplasty versus Minimally
ardiovascular Society; COPD, chronic obstructive pulmonary disease; EF, e
VEF, left ventricular ejection fraction; MI, myocardial infarction; MIDCAB
rtery bypass; PCI, percutaneous coronary intervention.
ABLE 2. Patient characteristics
OPCAB PCI
ge (mean y) 58.9 (9.8) 58.2 (10.1)
emale (%) 31 34
iabetic (%) 21 23
istory of MI (%) 29 32
moker (%) 30 33
yperlipidemia (%) 61 61
rossovers (%) 4.8 2.0
I, Myocardial infarction; OPCAB, off-pump coronary artery bypass; PCI,
sercutaneous coronary intervention.
26 The Journal of Thoracic and Cardiovascular Surgery ● Marctents,24,25,27,30,33 whereas one trial34 used either sirolimus-
luting (Cypher; Cordis, Roden, The Netherlands) or
aclitaxel-eluting (Taxus; Boston Scientific, Galway, Ire-
and) stents. Anticoagulation after stent placement consisted
f ticlopidine/clopidogrel and aspirin in 5 trials,24,25,27,30,34
nd was not stated in one trial.33 Ticlopidine/clopidogrel
as maintained for 4 weeks in the case of bare metal stents
nd 6 months for drug-eluting stents. Crossovers from
PCAB to PCI occurred in 4.8% of patients, whereas
rossovers from PCI to OPCAB occurred in 2.0% of pa-
ients after randomization.
Table 3 and Figures 2 to 4 outline the results. Com-
ared with PCI, OPCAB reduced the risk of reinterven-
ion for ischemia at 1 to 5 years by 76% (OR 0.24, 95%
I 0.15– 0.40). The odds of reintervention did not differ
n hospital (OR 0.77, 95% CI 0.35–1.68) or at 6 months
OR 0.45, 95% CI 0.16 –1.29). Angina recurrence was
nts Intervention Year Country
sions of proximal MIDCAB 2000-2001 Poland
D stenosis; elective, MIDCAB 1997-2001 Germany
s of type B2 or C;
ater; first-time
MIDCAB 1997-1999 Netherlands
ultiple-vessel
unstable angina
I–IIB). Excluded left
s, poor LVEF,
ularization, recent
cal
or PCI within 6 mo
OPCAB/
MIDCAB
1998-2000 Netherlands
ximal LAD stenosis
r urgent. Excluded
ed within 24 h),
D, previous
total occlusion of
MIDCAB 1999-2001 United
Kingdom
h-grade lesion
nal diameter) in
luded AMI, prior
arization, or total
MIDCAB 2003 Korea
-LAD OPCAB/
MIDCAB
1997-2003 European/
Asian
sive Surgery Trial; CABG, coronary artery bypass graft; CCS, Canadian
n fraction; LAD, left anterior descending; LITA, left internal thoracic artery;
mally invasive direct coronary artery bypass; OPCAB, off-pump coronaryPatie
pe le
l LA
nosi
r gre
or m
le or
lass
nosi
vasc
surgi
tion,
d pro
ive o
equir
COP
tion,
d hig
lumi
. Exc
scul
AD
LITA
Inva
jectio
, miniignificantly reduced in favor of OPCAB in hospital (OR
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CD.42, 95% CI 0.25– 0.71) and at 1 to 5 years (OR 0.54,
5% CI 0.34 – 0.87), but not at 6 months (OR 0.57, 95%
I 0.25–1.28). MACE was significantly reduced in favor
f OPCAB at 6 months (OR 0.40, 95% CI 0.23– 0.69) and
t 1 to 5 years (0.44, 95% CI 0.30 – 0.63). Event-free
urvival was significantly improved at 6 months and at 1
o 5 years (Table 3). Six-month stenosis rates were sig-
ificantly reduced (OR 0.31, 95% CI 0.18 – 0.55). How-
ver, hospital LOS was significantly increased with
PCAB versus PCI (WMD 4.0, 95% CI 2.4 –5.7). When
ubgroup analysis was performed for trials using bare
etal stents and excluding studies using drug-eluting
tents, the results did not materially change with the
xception of reintervention at 6 months, which was sig-
ABLE 3. Results
utcome OPCAB (%) PC
eath, in hospital 1.3
eath, 6 months 2.5
eath, 1 to 5 years 5.9
MI, in hospital 3.0
MI, 6 months 2.8
MI, 1 to 5 years 4.0
troke, in hospital 0.5
troke, 6 months 0.6
troke, 1 to 5 years 0
ngina recurrence, in hospital 6.8 1
ngina recurrence, 6 months 13.1 1
ngina recurrence, 1 to 5 years 12.8 2
eintervention, in hospital 2.3
eintervention, 6 months 6.8 1
eintervention, 1 to 5 years 5.8 1
ACE, in hospital 2.8
ACE, 6 months 8.9 2
ACE, 1 to 5 years 14.3 2
vent-free survival, 6 months 87.6 7
vent-free survival, 1 to 5 years 83.8 6
tenosis, 6 months 10.3 2
ound complications, in hospital 3.5
MI, Acute myocardial infarction; CI, confidence intervals; MACE, major ad
CI, percutaneous coronary intervention.
Figure 2. Reintervention at 1 to 5 years: OPCAB ve
percutaneous coronary intervention.
The Journal of Thoracicificantly reduced in favor of OPCAB (OR 0.26, 95% CI
.14 – 0.49) (Table 4).
Compared with PCI, all-cause mortality, stroke, myocar-
ial infarction, and wound complications were not reduced
ith OPCAB at any time point (Table 3). Other outcomes
ncluding atrial fibrillation, renal dysfunction, inotropic re-
uirements, need for intra-aortic balloon pump, blood trans-
usion requirements, re-exploration for bleeding, ICU LOS,
nd neurocognitive function were insufficiently reported to
erform meta-analysis.
OL
OL was measured in 2 studies, and results were not
ombined through meta-analysis because different QOL
OR (95% CI) I2 (%) P value for effect
2.01 (0.56–7.23) 0 .28
1.61 (0.51–5.05) 0 .42
1.51 (0.72–3.18) 20 .27
1.11 (0.5–2.47) 0 .8
0.93 (0.35–2.49) 17 .81
0.92 (0.45–1.9) 0 .82
1.56 (0.29–8.34) 0 .61
0.43 (0.6–2.95) 0 .39
0.35 (0.03–3.97) 0 .4
0.42 (0.25–0.71) 0 .0001
0.57 (0.25–1.28) 66 .17
0.54 (0.34–0.87) 38 .01
0.77 (0.35–1.68) 0 .51
0.45 (0.16–1.29) 60 .14
0.24 (0.15–0.40) 0 .0001
0.86 (0.27–2.74) 22 .80
0.40 (0.23–0.69) 25 .001
0.44 (0.30–0.63) 0 .0001
2.53 (1.50–4.27) 0 .0001
2.32 (1.62–3.32) 0 .0001
0.31 (0.18–0.55) 47 .0001
2.54 (0.62–10.45) 0 .20
coronary events; OPCAB, off-pump coronary artery bypass; OR, odds ratio;
PCI. OPCAB, off-pump coronary artery bypass; PCI,I (%)
0.4
1.5
3.5
2.9
3.4
4.8
0.3
1.9
1.1
3.8
8.7
3.3
3.2
5.2
9.7
3.8
1.6
6.8
3.7
9.9
8.0
0.9
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A
CDcales were used. Eefting and associates33 measured
uroQOL (EQ-5D) and short-form health survey (SF-36)
nd found that at 1 month, EQ-5D and many domains of the
F-36 were significantly higher after PCI than after
PCAB, but this difference was no longer found at 1 year.
n addition, Reeves and colleagues24 found that EQ-5D,
F-36, Seattle Angina Questionnaire (SAQ) and Coronary
evascularization and Outcome Questionnaire (CROQ) at 3
onths, 6 months, and 12 months tended to favor OPCAB,
lthough only three domains reached statistical significance
SF-36 mental composite score at 12 months, P .04; SAQ
reatment satisfaction score at 3 months, P  .02; CROQ
ognitive score at 3 months, P  .04). SAQ dimensions of
ngina stability and frequency and CROQ physician and
ognitive dimensions suggest the most consistent benefit of
PCAB, but without statistical significance. Since a large
umber of comparisons were tested for QOL domains, the
nding of statistical significance should be interpreted with
aution owing to the increased risk of spurious positive
ndings with multiple testing. Eefting and colleagues33
Figure 3. MACE at 1 to 5 years: OPCAB versus PCI.
coronary artery bypass; PCI, percutaneous coronary in
Figure 4. Angina recurrence at 1 to 5 years: OPCAB v
percutaneous coronary intervention.
ABLE 4. Subgroup analysis: Bare metal stent angioplasty
utcome OPCAB (%) PCI
ngina recurrence, in hospital 6.8 13
ngina recurrence, 1 to 5 years 12.8 23
eintervention, 1 to 5 years 3.7 13PCAB, off-pump coronary artery bypass; PCI, percutaneous coronary interven
28 The Journal of Thoracic and Cardiovascular Surgery ● Marcound an estimated gain in quality-adjusted life-years was
.82 after PCI and 0.79 after OPCAB, and Reeves and
oworkekrs24 estimated gain in quality-adjusted life-years
f 0.77 after PCI and 0.82 after OPCAB.
conomic Outcomes
hree trials reported economic outcomes.24,25,33 When di-
ect costs during hospitalization or up to 1 year were con-
idered, OPCAB was more costly than PCI, despite the
dded costs of increased reinterventions with PCI over 6- to
2-month follow-up (Table 5). Estimates of incremental
ost-effectiveness were reported in 2 trials, with widely
arying results (Table 6). Pooled analysis of economic
utcomes was not practical owing to differences in methods
f collecting and reporting costs.
iscussion
ompared with PCI, OPCAB decreased the odds of rein-
ervention by 76%, recurrent angina by 46%, and occur-
E, major adverse coronary events; OPCAB, off-pump
ntion.
s PCI. OPCAB, off-pump coronary artery bypass; PCI,
cluding drug-eluting stents)
OR (95% CI) I2 (%) P value for effect
0.42 (0.25–0.71) 0 .0001
0.25 (0.12–0.54) 0 .0001
0.25 (0.12–0.54) 0 .0001MAC
terveersu(ex
(%)
.8
.3
.4tion; OR, operating room; CI, confidence interval.
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CDence of MACE by 56% at 1 to 5 years, requiring an average
ospital LOS that is 4 days or greater.
These results have significant implications when pro-
ected over a large population. For example, given the
ggregate estimates in this meta-analysis, for every 1000
ow-risk patients undergoing off-pump surgery (ie, primar-
ly left internal thoracic artery–left anterior descending ar-
ery revascularization), there will be an estimated 105 fewer
atients with angina, 143 fewer patients requiring reinter-
ention, and 125 fewer patients with MACE at 1 to 5 years.
hether OPCAB increases or decreases overall costs over
he midterm to long-term relative to PCI remains uncertain,
ecause few studies reported resource utilization.
Studies comparing CCAB and PCI (angioplasty) have
emonstrated an improvement in short-term outcomes with
CI, such as length of hospital stay and cost. Unfortunately,
atients randomized to PCI typically experience higher rates
f recurrent angina requiring repeat revascularization pro-
edures. The largest trial to date of angioplasty versus
CAB, the BARI trial (Bypass Angioplasty Revasculariza-
ion Investigation), demonstrated that patients who had di-
betes or multiple-vessel disease derived the greatest benefit
rom CCAB.12,13 Although trials comparing percutaneous
oronary stenting and CCAB have demonstrated a reduction
n recurrent angina and restenosis compared with angio-
lasty, they still do not demonstrate equivalent efficacy to
CAB in these outcomes.7,9,35 The recent introduction of
rug-eluting stents may further reduce the occurrence of
ecurrent angina and restensois36,37; however, it is still
nclear whether they will prove equivalent to CCAB pro-
edures. Comparisons of drug-eluting stents to CCAB may
e incomplete until optimal drug dosage and delivery have
ABLE 5. Direct costs during hospitalization (or up to 1 ye
tudy
OPCAB mean direct cost
(SD) per patient
isowski25 (02) 2000 USD at 30 d
efting33 (03) (OctoStent) 7508 EUR in hospital
(9518 EUR at 1 y)
eeves24 (02) 2114 GBP in hospital
2681 GBP at 1 y
UR, Euro; GBP, Great Britain pound; OPCAB, off-pump coronary artery byp
ollars.
ABLE 6. Cost-effectiveness
tudy OPCAB total* cost per QALY
efting33 (03) (OctoStent) 1,1209/0.79
eeves24 (04) 2681/0.82
UR, Euro; GBP, Great Britain pound; OPCAB, off-pump coronary artery by
Direct  indirect costs at 1 year.
The Journal of Thoraciceen ascertained, and one drug-eluting stent may not be
qually efficacious to others.36,37
Unfortunately, economic outcomes were insufficiently
eported in the present review to allow for conclusions
egarding incremental cost-effectiveness for OPCAB and
CI. Although initial costs favor PCI over CCAB,
ollow-up costs related to repeat revascularization reduce
ny economic advantage of PCI.38 The use of drug-eluting
tents, which reduces the need for revascularization, may
otentially reduce these reintervention costs related to PCI.
owever, numerous studies have suggested that drug-
luting stents, at current prices, are not likely to be consid-
red cost-effective.39-41 Indeed, a cost-effectiveness analy-
is from the province of Ontario, Canada, found that the
ncremental cost of drug-eluting stents compared with bare
etal stents for 1 quality-adjusted life-year was $223,580
anadian dollars in non–post myocardial infarction diabetic
atients having discrete lesions and $477,736 Canadian
ollars in these same patients with long or narrow lesions.42
Whereas the short-term and medium-term benefits of
PCAB surgery seem clear in the hands of experienced
urgeons,15,16 the long-term results are too infrequently
eported in the current literature to draw definitive conclu-
ions. Of particular concern is graft patency, which has been
emonstrated to be inferior in one randomized trial of
PCAB versus CCAB43 and not inferior in several other
andomized trials.44-46 Although OPCAB initially was in-
roduced with widespread enthusiasm, its frequency seems
o have reached a plateau and it is being reserved increas-
ngly for higher-risk patients with significant aortic
isease.16
PCI mean direct cost
(SD) per patient Summary
1600 USD at 30 d MIDCAB  PCI ; P not reported
5013 EUR in hospital
(7043 EUR at 1 y)
OPCAB  PCI; P  .01
OPCAB  PCI; P  .01
1093 GBP in hospital
1789 GBP at 1 y
OPCAB  PCI; P not reported
OPCAB  PCI; P not reported
PCI, percutaneous coronary intervention; SD, standard deviation; USD, US
CI total* cost per QALY Incremental cost per QALY
$8276/0.82 2933/0.03 97,767 EUR/QALY
1789/0.77 892/0.02 44,600 GBP/QALY
PCI, percutaneous coronary intervention; QALY, quality-adjusted life year.ar)
ass;P
pass;and Cardiovascular Surgery ● Volume 133, Number 3 629
cp
c
l
S
M
w
c
t
b
r
o
t
e
t
c
h
c
t
d
a
s
h
s
r
a
b
i
M
c
f
c
f
a
d
y
l
p
C
I
a
w
h
w
R
1
1
1
1
1
1
1
1
1
1
Surgery for Acquired Cardiovascular Disease Bainbridge et al
6
A
CDGiven an increasing number of options for treatment of
oronary artery disease, the need to identify subgroups of
atients who benefit from a specific treatment option be-
omes imperative. The challenge is in balancing short- and
ong-term risk with benefits.
trengths, Limitations, and Generalizability
ost trials for OPCAB versus PCI included only patients
ith single-vessel disease of the left anterior descending
oronary artery, precluding inferences to patients with mul-
ivessel disease. Whether drug-eluting stents, which have
een shown to significantly reduce restenosis and repeat
evascularization rates by up to 83%, would mitigate the
bserved differences in restenosis and reintervention be-
ween OPCAB and PCI remains to be addressed.47 How-
ver, randomized studies of drug-eluting stents have failed
o demonstrate improvements in rates of mortality or myo-
ardial infarction.36
The rigor of this meta-analysis, as evidenced by compre-
ensive searches for randomized trials of all relevant out-
omes and comparisons in any language, and the adherence
o QUOROM recommendations, serves to increase confi-
ence that this represents a complete summary of best
vailable evidence. When heterogeneity was accounted for
tatistically, the conclusions remained unchanged for each
eterogeneous outcome. Although the median Jadad quality
core was 3 out of 5, this is common for meta-analysis of
andomized trials (especially those in the field of surgery)
nd does not necessarily mean the trials were of low quality,
ut rather that key methodologic details were not reported.48
Although our analysis delineates the landscape of exist-
ng evidence, it also serves to highlight gaps that remain.
ost notable is the lack of research defining long-term
linical, economic, and QOL outcomes associated with dif-
ering revascularization techniques. Accordingly, theoreti-
al concerns about the quality and patency of grafts per-
ormed on the beating heart have not been adequately
ddressed by long-term follow-up of randomized trials to
ate, although survival and reintervention rates at up to 5
ears have been encouraging (Table 3). Also notable is the
ack of randomized controlled studies in higher-risk
atients.
onclusions
n conclusion, OPCAB reduces the need for reintervention,
ngina recurrence, and incidence of MACE at 1 to 5 years
hen compared with PCI. The overall impact on QOL and
ealth system resource utilization remains unknown and
arrants further study.
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